Roche's Columvi Meets Main Goal in Lymphoma Phase 3 Trial
By Adria Calatayud
Roche Holding said its Columvi drug helped lymphoma patients who had received at least one prior treatment live longer in a phase 3 clinical trial, meeting the primary goal of the study.
The Swiss pharmaceutical giant said Monday that Columvi, in combination with chemotherapy, showed a statistically significant improvement in overall survival for people with diffuse large B-cell lymphoma--a form of blood cancer--who had received at least one prior line of therapy and weren't candidates for transplant of their own stem cells.
Roche said safety of the drug combination appeared consistent with the known safety profiles of the individual medicines.
Data from the trial will be submitted to health authorities, the company said. Roche intends to publish more details at an upcoming medical meeting, it said.
Columvi already received approval by the U.S. Food and Drug Administration and conditional authorization from the European Commission to treat people with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of therapy, Roche said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
April 15, 2024 01:39 ET (05:39 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track